Objective:To investigate the effects of liraglutide combined with metformin on lipid metabolism and micro-inflammatory response in T2DM patients with obesity.Methods:A total of 138 T2DM patients with obesity who were ...Objective:To investigate the effects of liraglutide combined with metformin on lipid metabolism and micro-inflammatory response in T2DM patients with obesity.Methods:A total of 138 T2DM patients with obesity who were treated in the hospital between May 2016 and August 2017 were divided into control group (n=69) and liraglutide group (n=69) by random number table method. Control group received metformin therapy and liraglutide group received liraglutide combined with metformin therapy, which lasted for 3 months. The differences in the levels of insulin resistance indexes, cholesterol-related indexes, apolipoprotein and inflammatory mediators were compared between the two groups.Results:After 3 months of treatment, serum insulin resistance-related indexes FBG and FINS levels of liraglutide group were lower than those of control group;serum cholesterol-related indexes TC and LDL-C contents were lower than those of control group whereas HDL-C content was higher than that of control group;serum apolipoprotein Apo AⅠ and Apo AⅡ contents were higher than those of control group whereas Apo CⅡ and Apo CⅢ contents were lower than those of control group;serum inflammatory mediators IL-6, IL-17 and TNF-α contents were lower than those of control group.Conclusion:Metformin combined with liraglutide therapy can further optimize the glycolipid metabolism and inhibit the micro-inflammatory state in T2DM patients with obesity.展开更多
文摘Objective:To investigate the effects of liraglutide combined with metformin on lipid metabolism and micro-inflammatory response in T2DM patients with obesity.Methods:A total of 138 T2DM patients with obesity who were treated in the hospital between May 2016 and August 2017 were divided into control group (n=69) and liraglutide group (n=69) by random number table method. Control group received metformin therapy and liraglutide group received liraglutide combined with metformin therapy, which lasted for 3 months. The differences in the levels of insulin resistance indexes, cholesterol-related indexes, apolipoprotein and inflammatory mediators were compared between the two groups.Results:After 3 months of treatment, serum insulin resistance-related indexes FBG and FINS levels of liraglutide group were lower than those of control group;serum cholesterol-related indexes TC and LDL-C contents were lower than those of control group whereas HDL-C content was higher than that of control group;serum apolipoprotein Apo AⅠ and Apo AⅡ contents were higher than those of control group whereas Apo CⅡ and Apo CⅢ contents were lower than those of control group;serum inflammatory mediators IL-6, IL-17 and TNF-α contents were lower than those of control group.Conclusion:Metformin combined with liraglutide therapy can further optimize the glycolipid metabolism and inhibit the micro-inflammatory state in T2DM patients with obesity.
